TY - JOUR
T1 - Toward Overcoming Treatment Failure in Rheumatoid Arthritis
AU - Wang, Zhuqian
AU - Huang, Jie
AU - Xie, Duoli
AU - He, Dongyi
AU - Lu, Aiping
AU - Liang, Chao
N1 - Funding Information:
This review is supported by the Natural Science Foundation Council of China (81700780, 81922081, 82172386, 81774114 and 82074234), The Science, Technology and Innovation Commission of Shenzhen (JCYJ20210324104201005), the Croucher Foundation (Gnt#CAS14BU/CAS14201), the 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab) (2020B1212030006) and the National administration of Traditional Chinese Medicine, regional Chinese medicine (Specialist) diagnosis and Treatment Center Construction project rheumatology.
Publisher Copyright:
Copyright © 2021 Wang, Huang, Xie, He, Lu and Liang.
PY - 2021/12/23
Y1 - 2021/12/23
N2 - Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a “trial-and-error” approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data.
AB - Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a “trial-and-error” approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data.
KW - biomarker
KW - DMARDs
KW - precision medicine
KW - rheumatoid arthritis
KW - treatment failure
UR - http://www.scopus.com/inward/record.url?scp=85122351319&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2021.755844
DO - 10.3389/fimmu.2021.755844
M3 - Journal article
C2 - 35003068
AN - SCOPUS:85122351319
SN - 1664-3224
VL - 12
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 755844
ER -